ArticleMediators of inflammation2026
Integrating Inflammation and Lipid Metabolism Biomarkers for Early Risk Stratification in Acute Cerebral Infarction: A Nomogram-Based Approach.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating Inflammation and Lipid Metabolism Biomarkers for Early Risk Stratification in Acute Cerebral Infarction: A Nomogram-Based Approach.Mediators of inflammation · 2026Article
- Systemic inflammatory biomarkers CAR and IL-6: correlation with neurological deficit and short-term prognosis of intracerebral hemorrhage.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo assess the prognostic value of the homocysteine-to-high-density lipoprotein cholesterol (Hcy/HDL-C) ratio and the high-sensitivity C-reactive protein-to-albumin (hs-CRP/Alb) ratio as biomarkers for predicting functional outcomes in acute cerebral infarction (ACI) patients treated with recombinant tissue plasminogen activator (rt-PA).
methodsA retrospective analysis was conducted on 204 ACI patients who received rt-PA. Patients were classified into two groups based on their functional outcomes at 3 months poststroke: good (modified Rankin scale [mRS] ≤ 2) and poor (mRS > 2). Logistic regression and restricted cubic spline (RCS) analyses were performed to evaluate the association between Hcy/HDL-C and hs-CRP/Alb ratios with functional outcomes. A predictive nomogram was developed incorporating these biomarkers, baseline NIHSS scores, and atrial fibrillation. The performance of this nomogram was compared to traditional risk models.
resultsElevated Hcy/HDL-C and hs-CRP/Alb ratios were identified as independent predictors of poor functional outcomes in ACI patients (p < 0.05). The nomogram, incorporating these biomarkers along with NIHSS scores and atrial fibrillation, demonstrated superior predictive performance with a C-index of 0.936 and an AUC of 0.935, outperforming traditional risk models (C-index = 0.782). Subgroup analysis revealed that Hcy/HDL-C was more predictive in patients with large-artery atherosclerosis (LAA), while hs-CRP/Alb showed stronger prognostic value in patients with cardioembolic strokes.
conclusionThe Hcy/HDL-C and hs-CRP/Alb ratios serve as independent and valuable biomarkers for predicting poor outcomes in ACI patients post-rt-PA treatment. The nomogram incorporating these biomarkers provides superior prognostic accuracy and could be a useful tool for personalized risk assessment and management in ACI patients following thrombolytic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.